Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project-Reference-Cited by-同舟云学术

Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project

Published:2015-07-07 Issue: Volume:25 Page:56-65
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Huerta Consuelo¹,Abbing-Karahagopian Victoria²,Requena Gema³,Oliva Belén¹,Alvarez Yolanda⁴,Gardarsdottir Helga²⁵,Miret Montserrat⁶,Schneider Cornelia⁷,Gil Miguel¹,Souverein Patrick C.²,De Bruin Marie L.²,Slattery Jim⁴,De Groot Mark C. H.²,Hesse Ulrik⁸,Rottenkolber Marietta⁹,Schmiedl Sven¹⁰¹¹,Montero Dolores¹,Bate Andrew¹²,Ruigomez Ana¹³,García-Rodríguez Luis Alberto¹³,Johansson Saga¹⁴,de Vries Frank²¹⁵¹⁶,Schlienger Raymond G.¹⁷,Reynolds Robert F.¹⁸,Klungel Olaf H.²¹⁹,de Abajo Francisco José³²⁰

Affiliation:

1. Division of Pharmacoepidemiology and Pharmacovigilance, Medicines for Human Use Department; Spanish Agency for Medicines and Medical Devices (AEMPS); Madrid Spain

2. Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology; Utrecht University; Utrecht The Netherlands

3. Pharmacology Unit, Department of Biomedical Sciences II, School of Medicine and Health Sciences; University of Alcalá; Madrid Spain

4. European Medicines Agency (EMA); London UK

5. Department of Clinical Pharmacy, Division Laboratory and Pharmacy; University Medical Center Utrecht; Utrecht The Netherlands

6. Merck KGaA; Geneva Switzerland

7. Division Clinical Pharmacy and Epidemiology; University of Basel; Switzerland

8. National Institute for Health Data and Disease Control; Copenhagen Denmark

9. Institute for Medical Information Sciences, Epidemiology, and Biometry; Ludwig-Maximilians-Universitaet München; Munich Germany

10. Department of Clinical Pharmacology, School of Medicine, Faculty of Health; Witten/Herdecke University; Witten Germany

11. Philipp Klee-Institute for Clinical Pharmacology; HELIOS Clinic Wuppertal; Wuppertal Germany

12. Epidemiology; Pfizer Ltd; Tadworth UK

13. Spanish Center for Pharmacoepidemiological Research (CEIFE); Madrid Spain

14. AstraZeneca R&D; Mölndal Sweden

15. MRC Epidemiology Resource Centre; Southampton General Hospital; Southampton UK

16. School CAPHRI; Maastricht University; The Netherlands

17. Quantitative Safety and Epidemiology; Novartis Pharma AG; Basel Switzerland

18. Epidemiology; Pfizer Research & Development; New York USA

19. University Medical Center Utrecht (UMCU); Julius Center for Health Sciences and Primary Care; The Netherlands

20. Clinical Pharmacology Unit; University Hospital Príncipe de Asturias; Madrid Spain

Funder

Innovative Medicines Initiative Joint Undertaking

European Union's Seventh Framework Programme

European Federation of Pharmaceutical Industries and Association

Pfizer

Astra Zeneca

Top-Institute PHARMA

EU Innovative Medicines Initiative

Merck Serono SA-Geneva

Top Institute Pharma

AstraZeneca R&D, Mölndal, Sweden

Bayer Pharma AG, Berlin, Germany

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pds.3825/fullpdf

Reference47 articles.

1. Danish Health and Medicines Authority Effective effort against the excessive use of benzodiazepines in Denmark http://www.dkma.dk/en/topics/statistics-prices-and-reimbursement/statistics-and-analyses/analyses/consumption-analyses/effective-effort-against-the-excessive-u--in-denmark 2012

2. Spanish Agency for Medicines and Medical Devices (AEMPS) Uso de Benzodiacepinas en España (1992-2006) http://www.aemps.gob.es/medicamentosUsoHumano/observatorio/docs/ansioliticos_hipnoticos.pdf 2012

3. Medicines and Healthcare products Regulatory Agency (MHRA) Addiction to benzodiazepines and codeine: supporting safer use. July 2011 http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON123123 2012

4. The prescribing of psychotropic drugs by primary care physicians: an international collaborative study;Linden;J Clin Psychopharmacol,1999

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Psychotropic prescribing after hospital discharge in survivors of critical illness, a retrospective cohort study (2012–2019);Journal of the Intensive Care Society;2024-01-19

2. Privatverordnungen von Benzodiazepinen und Z-Substanzen in Ost- und Westdeutschland – eine Sekundärdatenanalyse;Das Gesundheitswesen;2023-12

3. Self-medication with Novel Psychoactive Substances (NPS): a Systematic Review;International Journal of Mental Health and Addiction;2023-11-28

4. Impact of a publicly-funded pharmacare program policy on benzodiazepine dispensing among children and youth: a population-based natural experiment;BMC Pediatrics;2023-10-19

5. Trajectories of Benzodiazepine Use among Older Adults from a Concordance-with-Guidelines Perspective: A Nationwide Cohort Study;Drugs & Aging;2023-08-08